SAT-312 Beta-Arrestin 2 Is Required for Dopamine Receptor Type 2 Inhibitory Effects on Akt Phosphorylation and Cell Proliferation in Pituitary Tumors

Dopamine receptor type 2 (DRD2) agonists are the first-choice treatment for PRL-secreting pituitary tumors but are poorly effective in non-functioning pituitary neuroendocrine tumors (NF-PitNETs). DRD2 reduces AKT phosphorylation in lactotrophs, but no data are available in NF-PitNETs. DRD2 effects...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Endocr Soc
Glavni autori: Mangili, Federica, Giardino, Elena, Treppiedi, Donatella, Barbieri, Anna Maria, Catalano, Rosa, Locatelli, Marco, Lania, Andrea G, Spada, Anna, Arosio, Maura, Mantovani, Giovanna, Peverelli, Erika
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2020
Teme:
Neuroendocrinology and Pituitary
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7209574/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.503
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items